Ken Griffin Curis Inc Transaction History

Citadel Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.57 - $0.99 $3,966 - $6,889	6,959 Added 852.82%	7,775 $6,000
Q1 2023 May 15, 2023	SELL	$0.51 - $0.78 $20,818 - $31,840	-40,821 Reduced 98.04%	816 $0
Q4 2022 Feb 14, 2023	BUY	$0.47 - $17.22 $822 - $30,134	1,750 Added 4.39%	41,637 $22,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $15.01 $377,049 - $7.65 Million	-509,527 Reduced 92.74%	39,887 $28,000
Q2 2022 Aug 15, 2022	SELL	$0.71 - $2.43 $225,471 - $771,682	-317,565 Reduced 36.63%	549,414 $540,000
Q1 2022 May 16, 2022	BUY	$2.31 - $5.13 $1.84 Million - $4.08 Million	794,894 Added 1102.72%	866,979 $2.06 Million
Q4 2021 Feb 14, 2022	SELL	$4.45 - $8.09 $888,669 - $1.62 Million	-199,701 Reduced 73.48%	72,085 $343,000
Q3 2021 Nov 15, 2021	BUY	$6.94 - $8.85 $1.07 Million - $1.37 Million	154,787 Added 132.3%	271,786 $2.13 Million
Q2 2021 Aug 16, 2021	SELL	$7.45 - $16.27 $1.42 Million - $3.1 Million	-190,450 Reduced 61.95%	116,999 $944,000
Q1 2021 May 17, 2021	BUY	$8.78 - $12.8 $2.34 Million - $3.41 Million	266,385 Added 648.71%	307,449 $3.48 Million
Q4 2020 Feb 16, 2021	BUY	$1.08 - $8.2 $16,412 - $124,615	15,197 Added 58.75%	41,064 $336,000
Q3 2018 Nov 13, 2018	BUY	$1.38 - $1.94 $35,696 - $50,181	25,867 New	25,867 $0

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.